Since LNCaP and 22Rv1 are both androgen receptor (AR)-dependent prostate cancer cells, we also selected the AR-independent cell line PC3 for comparative studies in our subsequent experiments, as PC3 requires less drug concentration to achieve similar effects, making it more drug-sensitive. The gene discussed is AR; the disease is prostate carcinoma.